In the semaglutide arm only, other non-prespecified baseline variables (age, ethnicity, diabetes status, sex, type of surgery, time since surgery (months), meal-stimulated change in GLP-1 at baseline, postoperative %WL (from DOS to randomization)) and maximum %WL achieved after surgery or MBS response (weight regain versus suboptimal post-surgery weight loss) were added to the primary outcome linear regression model for the semaglutide arm only (therefore omitting the treatment allocation covariate) to assess their relationship with %WL induced by semaglutide at 68 weeks
By contrast, exenatide and roflumilast were associated with greater uncertainty, with 95% credible intervals crossing the null
Nevertheless, empagliflozin consistently slowed eGFR decline compared with placebo across all subgroups [48]
Exact shelf life can vary based on specific storage conditions, handling, and the particular peptide batch
Inflammatory bowel disease and pancreatitis: a review